ondansetron has been researched along with Atrial Fibrillation in 3 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
Atrial Fibrillation: Abnormal cardiac rhythm that is characterized by rapid, uncoordinated firing of electrical impulses in the upper chambers of the heart (HEART ATRIA). In such case, blood cannot be effectively pumped into the lower chambers of the heart (HEART VENTRICLES). It is caused by abnormal impulse generation.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To provide further evidence of cardiovascular adverse effects of ondansetron, including new-onset atrial fibrillation, ST segment elevation, and chest pain subsequent to ondansetron administration, and to review cardiovascular adverse events related to several 5-hydroxytryptamine type 3 (5-HT(3)) receptor antagonists." | 7.75 | Coronary vasospasm and atrial fibrillation associated with ondansetron therapy. ( Havrilla, PL; Kane-Gill, SL; Reis, SE; Seybert, AL; Verrico, MM, 2009) |
| " She received 4 mg of ondansetron intravenously for postoperative nausea and vomiting prophylaxis at the end of the procedure and an additional 4 mg in the recovery room for nausea." | 7.72 | Atrial fibrillation after ondansetron for the prevention and treatment of postoperative nausea and vomiting: a case report. ( Kasinath, NS; Malak, O; Tetzlaff, J, 2003) |
| "To provide further evidence of cardiovascular adverse effects of ondansetron, including new-onset atrial fibrillation, ST segment elevation, and chest pain subsequent to ondansetron administration, and to review cardiovascular adverse events related to several 5-hydroxytryptamine type 3 (5-HT(3)) receptor antagonists." | 3.75 | Coronary vasospasm and atrial fibrillation associated with ondansetron therapy. ( Havrilla, PL; Kane-Gill, SL; Reis, SE; Seybert, AL; Verrico, MM, 2009) |
| " She received 4 mg of ondansetron intravenously for postoperative nausea and vomiting prophylaxis at the end of the procedure and an additional 4 mg in the recovery room for nausea." | 3.72 | Atrial fibrillation after ondansetron for the prevention and treatment of postoperative nausea and vomiting: a case report. ( Kasinath, NS; Malak, O; Tetzlaff, J, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Havrilla, PL | 1 |
| Kane-Gill, SL | 1 |
| Verrico, MM | 1 |
| Seybert, AL | 1 |
| Reis, SE | 1 |
| Miller, DR | 1 |
| Kasinath, NS | 1 |
| Malak, O | 1 |
| Tetzlaff, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Efficacy and Safety of Ramosetron in Patients Undergoing Off Pump Coronary Artery Bypass Surgery[NCT02139241] | 114 participants (Actual) | Interventional | 2013-06-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 other studies available for ondansetron and Atrial Fibrillation
| Article | Year |
|---|---|
Coronary vasospasm and atrial fibrillation associated with ondansetron therapy.
Topics: Antiemetics; Atrial Fibrillation; Coronary Vasospasm; Humans; Injections, Intravenous; Male; Middle | 2009 |
Arrhythmogenic potential of antiemetics: perspectives on risk-benefits.
Topics: Antiemetics; Arrhythmias, Cardiac; Atrial Fibrillation; Droperidol; Electrocardiography; Humans; Ind | 2003 |
Atrial fibrillation after ondansetron for the prevention and treatment of postoperative nausea and vomiting: a case report.
Topics: Antiemetics; Atrial Fibrillation; Female; Humans; Middle Aged; Ondansetron; Postoperative Nausea and | 2003 |